Apixaban is dear to me, but dearer still is warfarin

PACE - Pacing and Clinical Electrophysiology

Volumn 38, Issue 2, 2015, Pages 153-154

  Di Biase, Luigi ^a,b,c,d   Natale, Andrea ^b,c,e,f,g,h  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b TEXAS CARDIAC ARRHYTHMIA INSTITUTE   (United States)

^c The University of Texas at Austin   (United States)

^d UNIVERSITY OF FOGGIA   (Italy)

^e CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^f STANFORD UNIVERSITY   (United States)

^g CASE WESTERN RESERVE UNIVERSITY   (United States)

^h SCRIPPS CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDEXANET ALFA; ANTICOAGULANT AGENT; ANTIDOTE; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; FRESH FROZEN PLASMA; PLACEBO; PROTAMINE; WARFARIN; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ANTICOAGULATION; BLEEDING; BLOOD CLOTTING TIME; BRAIN ISCHEMIA; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; DEATH; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HEART ATRIUM FIBRILLATION; HEMATOLOGICAL PARAMETERS; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; THROMBOEMBOLISM; TREATMENT OUTCOME; ADVERSE EFFECTS; ATRIAL FIBRILLATION; COMPLICATION; EVIDENCE BASED MEDICINE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CATHETER ABLATION; EVIDENCE-BASED MEDICINE; FACTOR XA INHIBITORS; HUMANS; PYRAZOLES; PYRIDONES; THROMBOEMBOLISM; TREATMENT OUTCOME; WARFARIN;

EID: 84922624109     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/pace.12570     Document Type: Editorial

References (17)

1. Calkins H, Reynolds MR, Spector P, Sondhi M, Xu Y, Martin A, Williams CJ, et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: Two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol 2009; 2: 349-361.
2. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, Kim YH, et al. Prevalence and causes of fatal outcome in catheter ablation of atrial fibrillation. J Am Coll Cardiol 2009; 53: 1798-1803.
3. Scherr D, Sharma K, Dalal D, Spragg D, Chilukuri K, Cheng A, Dong J, et al. Incidence and predictors of periprocedural cerebrovascular accident in patients undergoing catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2009; 20: 1357-1363.
4. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, Kim YH, et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 2010; 3: 32-38.
5. Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R, Gallinghouse GJ, et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: Results from the role of coumadin in preventing thromboembolism in Atrial Fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation 2014; 129: 2638-2644.
6. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
7. Nagao T, et al.
8. Di Biase L, Burkhardt JD, Mohanty P, Trivedi C, Mohanty S, Santangeli P, Bai R, et al. Uninterrupted apixaban administration during ablation of non paroxysmal atrial fibrillation feasibility and safety. Heart Rhythm 2014; 11 (Suppl 5): S200 [PO02-95].
9. Lakkireddy D, Reddy YM, Di Biase L, Vallakati A, Mansour MC, Santangeli P, Gangireddy S, et al. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: Results from a multicenter prospective registry. J Am Coll Cardiol 2014; 63: 982-988.
10. Snipelisky D, Kauffman C, Prussak K, Johns G, Venkatachalam K, Kusumoto F,. A comparison of bleeding complications post-ablation between warfarin and dabigatran. J Interv Card Electrophysiol 2012; 35: 29-33.
11. Di Biase L,. Safety and efficacy of novel oral anticoagulants in the setting of atrial fibrillation ablation: Is it time to celebrate the "funeral" of warfarin? J Interv Card Electrophysiol 2014; 41: 103-105.
12. Di Biase L, Gaita F, Toso E, Santangeli P, Mohanty P, Rutledge N, Yan X, et al. Does periprocedural anticoagulation management of atrial fibrillation affect the prevalence of silent thromboembolic lesion detected by diffusion cerebral magnetic resonance imaging in patients undergoing radiofrequency atrial fibrillation ablation with open irrigated catheters? Results from a prospective multicenter study. Heart Rhythm 2014; 11: 791-798.
13. Goldstein JN, Thomas SH, Frontiero V, Joseph A, Engel C, Snider R, Smith EE, et al. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke 2006; 37: 151-155.
14. Dentali F, Marchesi C, Pierfranceschi MG, Crowther M, Garcia D, Hylek E, Witt DM, et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists: A meta-analysis. Thromb Haemost 2011; 106: 429-438.
15. Kim JS, Jongnarangsin K, Latchamsetty R, Chugh A, Ghanbari H, Crawford T, Yokokawa M, et al. The optimal range of international normalized ratio for radiofrequency catheter ablation of atrial fibrillation during therapeutic anticoagulation with warfarin. Circ Arrhythm Electrophysiol 2013; 6: 302-309.
16. Latchamsetty R, Gautam S, Bhakta D, Chugh A, John RM, Epstein LM, Miller JM, et al. Management and outcomes of cardiac tamponade during atrial fibrillation ablation in the presence of therapeutic anticoagulation with warfarin. Heart Rhythm 2011; 8: 805-808.
17. Aristotle, Nicomachean Ethics (I, 4, 1096a, 16-17).